immunotherapy

News

Roche's Tecentriq cocktail fails in newly-diagnosed ovarian ...

A cocktail of drugs including Roche’s Tecentriq has failed to improve progression-free survival in ovarian cancer patients, before or after surgery.

News

FDA approves Pfizer/Merck KGaA's Bavencio in first line blad...

The FDA has approved Pfizer and Merck KGaA’s immunotherapy Bavencio (avelumab) as a first line maintenance therapy in bladder cancer, setting up a rivalry with alternatives from Roche and A

News

Gilead to acquire half of cancer biotech Pionyr for $275m

Gilead has announced it is to acquire nearly half of the cancer drug biotech Pionyr, with an exclusive option to acquire the rest of the company as the big pharma continues its expansion in

News

Merck & Co's Keytruda outperforms chemo in MSI-High colorect...

Merck & Co’s Keytruda (pembrolizumab) immunotherapy has outperformed standard of care in untreated colorectal cancer with certain mutations, offering patients a single-agent therapy opt

News

Roche's TIGIT drug shows promise in untreated lung cancer

Roche has announced positive first phase 2 results from its new kind of cancer immunotherapy, showing that adding tiragolumab to its already approved Tecentriq creates a more potent combina

News

FDA to quickly review Roche's chemo-free lung cancer regimen

Roche’s challenge to Merck & Co’s immunotherapy Keytruda in first line lung cancer has gathered momentum after the FDA agreed to a fast review of Tecentriq monotherapy, preventing the n

Roche's Tecentriq cocktail fails in newly-diagnosed ovarian ...

FDA approves Pfizer/Merck KGaA's Bavencio in first line blad...

Gilead to acquire half of cancer biotech Pionyr for $275m

Merck & Co's Keytruda outperforms chemo in MSI-High colorect...

Roche's TIGIT drug shows promise in untreated lung cancer

FDA to quickly review Roche's chemo-free lung cancer regimen

Lilly gets back in infectious disease, via three M&A deals

Discover a new era of healthcare panel engagement: Grounded ...

immunotherapy

Editor's Picks